Consistent with previous reports of a pro-tumorigenic role of NOS in lung cancer [6–9], we demonstrate that in a genetically engineered mouse model of Kras-driven NSCLC, L-NAME treatment inhibits lung tumor growth, reduces tumor burden, increases median OS, and improves HR, even when treatment is initiated in the presence of established disease. The gene discussed is NOS2; the disease is lung carcinoma.